Trials / Completed
CompletedNCT03632759
Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D
Targeting Beta Cell Dysfunction in Longstanding T1D
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Carla Greenbaum, MD · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether 8 weeks of Liraglutide or Golimumab can transiently improve beta cell function in patients with longstanding Type 1 diabetes (T1D) who secrete proinsulin and little/no C-peptide.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Liraglutide | Participants will receive subcutaneous (SC) liraglutide for 8 weeks |
| DRUG | Golimumab | Participants will receive subcutaneous (SC) golimumab for 8 weeks |
Timeline
- Start date
- 2018-08-15
- Primary completion
- 2021-11-09
- Completion
- 2021-11-09
- First posted
- 2018-08-15
- Last updated
- 2022-01-24
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03632759. Inclusion in this directory is not an endorsement.